Cytosorbents Corp Q4 FY2024 earnings call

Management Statement and Operational Highlights: - CytoSorb is a leader in treating life-threatening conditions in intensive care units and cardiac surgery, with over 270,000 devices utilized in more than 70 countries worldwide. 2024 saw a 25% quarter-over-quarter increase in product revenue and a 15% year-over-year growth in full-year product revenue. - DrugSorb-ATR, an investigational device for reducing perioperative bleeding in cardiac surgery, has the FDA accepting its de novo application and being in interactive review, while the medical device license application to Health Canada is in advanced review. - In 2024, financial results included product revenue of $35.6M (+15% Y/Y), a gross margin of 71%, and improved operating loss. - A reorganization of the direct sales team in Germany was initiated to restore sales growth, with an expectation of a short-term decline in Germany sales in Q1 2025 but growth in the second half of 2025. - Clinical data from CytoSorb usage in septic shock and COVID-19 showed statistically significant improvements in survival and shorter mechanical support time. - Preparations for the commercial launch of DrugSorb-ATR in the US and Canada are underway, with clinical data to be showcased at major conferences, and a potential market size exceeding $1 billion as Brilinta becomes generic.

Segment Performance: CytoSorb, the flagship product, generated $35.6 million in core product sales in 2024. In the fourth quarter of 2024, product revenue reached $9.2 million, marking a 25% increase compared to the prior year. For the full year 2024, total product revenue was $35.6 million, representing a 15% year-over-year growth. This growth was driven by a 28% rise in direct sales outside of Germany and a 22% increase in distributor and partner sales, partially offset by flat growth in direct sales in Germany. The product gross margin remained robust at 71%. The second product, DrugSorb-ATR, is an investigational medical device with marketing applications submitted to the FDA and Health Canada, expecting regulatory decisions in 2025.

Guidance: - In 2025, a short-term modest decrease in product sales is expected in Q1 2025 in Germany due to the sales team reorganization, but growth is anticipated in the second half of the year. - The core business aims to approach near cash flow breakeven in the second half of 2025. - DrugSorb-ATR is expected to receive regulatory decisions from the FDA and Health Canada in 2025, with plans for a controlled market release and commercial launch preparation.

Risks: - Uncertainties in the German market due to post-COVID issues, hospital reforms, and other factors. - Potential delays in regulatory approvals from the FDA and Health Canada. - Operational challenges in scaling up the commercialization of DrugSorb-ATR.

Q: For DrugSorb and the regulatory process, have you seen any impacts from the new U.S. administration on regulator staffing?

A: Although there have been cuts to HHS including the FDA, these cuts are not targeting review personnel as detailed in reports.

Q: When getting clearance for DrugSorb, what are the key things you'll be looking for in a controlled launch?

A: We'll be looking to learn basics like getting into hospitals, navigating back committees, and how surgeons fit the product into their normal usage patterns from clinical sites.

Q: Thoughts on the size of the commercial organization needed to fully commercialize DrugSorb?

A: We see ourselves moving towards a sales force between 15% and 25% over time, focusing on getting sticky accounts early and seeing growth in usage across multiple surgeons in accounts.

Q: What metrics are needed to reach core business cash breakeven?

A: Continued revenue growth, 70%+ gross margins, and efficiency drives to continue reducing cash burn.

Q: What is the status of FDA review for DrugSorb?

A: As a FDA breakthrough device, we're in interactive review of our de novo application with FDA and in advanced review with Health Canada, expecting regulatory decisions in 2025.